Search results for "ErbB"

showing 10 items of 298 documents

Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 pati…

2007

<i>Objective:</i> We aimed to investigate the existence of associations between well-established and newly recognized biological and phenotypic features of breast cancer involved in tumor progression and prognosis. <i>Methods:</i> Ninety-eight cases of invasive breast cancer were assessed for the immunohistochemical expression of estrogen and progesterone receptors, Ki-67, HER2, Akt-1, and Notch-2, using the tissue microarray technique. Data regarding tumor histotype, histological grade, tumor size and lymph node status were collected for each patient and included in the analysis. <i>Results:</i> Several significant associations between histological and/o…

AdultOncologyCA15-3medicine.medical_specialtybreast cancer immunophenotypic analysis Notch-2 Akt-1 HER2/neuReceptor ErbB-2Breast NeoplasmsSettore MED/08 - Anatomia PatologicaHER2/neuImmunophenotypingPathology and Forensic MedicineBreast cancerImmunophenotypingInternal medicineBiomarkers TumormedicineHumansReceptor Notch2Notch 2Molecular BiologyProtein kinase BAgedAged 80 and overTissue microarraybiologybusiness.industryCancerCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseReceptors EstrogenTissue Array Analysisbiology.proteinFemaleReceptors ProgesteronebusinessProto-Oncogene Proteins c-akt
researchProduct

p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer

2006

AbstractBackground: The HER-2 receptor undergoes a proteolytic cleavage generating an NH2-terminally truncated fragment, p95HER-2, that is membrane-associated and tyrosine-phosphorylated. We have reported that p95HER-2, but not the full-length receptor, p185HER-2, correlated with the extent of lymph node involvement in patients with breast cancer and its expression was significantly enhanced in nodal metastatic tissue. These facts suggested an important role for p95HER-2 either as a marker or cause of metastasis and poor outcome in breast cancer. In this work, we have studied the prognostic value of p95HER-2 in breast cancer.Methods: Primary breast tumor tissues (n = 483) were from surgical…

AdultOncologyCancer ResearchPathologymedicine.medical_specialtyReceptor ErbB-2Breast NeoplasmsMetastasisBreast cancerRisk FactorsInternal medicineBiomarkers TumorTumor Cells CulturedmedicineCarcinomaHumansLymph nodeSurvival rateAgedAged 80 and overbusiness.industryCarcinoma Ductal BreastHazard ratioMiddle AgedPrognosismedicine.diseasePrimary tumorConfidence intervalSurvival RateCarcinoma Lobularmedicine.anatomical_structureReceptors EstrogenOncologyLymphatic MetastasisFemaleLymph NodesReceptors ProgesteronebusinessClinical Cancer Research
researchProduct

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Posit…

2015

Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant GeparSixto trial. Patients and Methods GeparSixto investigated the effect of adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response (pCR). A total of 580 tumors were evaluated before random assignment for stromal TILs and lymphocyte-predominant BC (LPBC). mRNA expression of immune-activating (CXCL9, …

AdultOncologyCancer Researchmedicine.medical_specialtyStromal cellReceptor ErbB-2medicine.medical_treatmentAntineoplastic AgentsTriple Negative Breast NeoplasmsCarboplatinchemistry.chemical_compoundLymphocytes Tumor-InfiltratingPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansAgedRandomized Controlled Trials as TopicChemotherapybusiness.industryTumor-infiltrating lymphocytesCancerFOXP3Middle AgedPrognosismedicine.diseaseNeoadjuvant TherapyCarboplatin3. Good healthCD8AGene Expression Regulation NeoplasticOncologychemistryChemotherapy AdjuvantCXCL9FemalebusinessJournal of Clinical Oncology
researchProduct

Expression Levels and Clinical-Pathological Correlations of HER2/neu in Primary and Metastatic Human Breast Cancer

2005

In this retrospective study we assessed the expression of the HER2/neu oncogene product in a series of 574 consecutive breast cancer cases, all recruited at the Maurizio Ascoli Cancer Center of Civico Hospital, in Palermo, between January 1998 and June 2003. The HER2/neu expression was evaluated using immunohistochemistry and scored from 0 to +3 as per FDA recommendations. The HER2/neu expression levels were related to the clinical-pathological features of the disease, including tumor size, nodal and menopausal status, estrogen and progesterone receptors, and hormonal or chemotherapeutic treatment. In 108 patients with a follow-up period of 3 years or more, the HER2/neu expression was also …

AdultOncologymedicine.medical_specialtyTime FactorsReceptor ErbB-2medicine.drug_classBreast NeoplasmsDisease-Free SurvivalGeneral Biochemistry Genetics and Molecular BiologyHER2/neuBreast cancerHistory and Philosophy of ScienceInternal medicineBiomarkers TumormedicineHumansNeoplasm Metastasisskin and connective tissue diseasesPathologicalIn Situ Hybridization FluorescenceAgedRetrospective StudiesbiologyOncogenebusiness.industryGeneral NeuroscienceCancerRetrospective cohort studyMiddle Agedmedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticTreatment OutcomeEstrogenLymphatic Metastasisbiology.proteinImmunohistochemistryFemalebusinessAnnals of the New York Academy of Sciences
researchProduct

VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab

2008

AIM: To gain mechanistic insights into the role played by epidermal growth factor receptor (EGFR) in the regulation of vascular endothelial growth factors (VEGFs) in colorectal cancer (CRC). METHODS: The impact of high-level expression of the growth factor receptors EGFR and VEGF receptor (VEGFR)3 and the VEGFR3 ligands VEGF-C and VEGF-D on disease progression and prognosis in human CRC was investigated in 108 patients using immunohistochemistry. Furthermore, the expression of the lymphangiogenic factors in response to the modulation of EGFR signalling by the EGFR-targeted monoclonal antibody cetuximab was investigated at the mRNA and protein level in human SW480 and SW620 CRC cell lines an…

AdultPathologymedicine.medical_specialtyColorectal cancerTransplantation HeterologousVascular Endothelial Growth Factor CVascular Endothelial Growth Factor DCetuximabAntineoplastic AgentsMice SCIDAntibodies Monoclonal HumanizedMiceGrowth factor receptorMice Inbred NODCell Line TumorMedicineAnimalsHumansEpidermal growth factor receptorneoplasmsAgedColorectal CancerAged 80 and overCetuximabbiologyintegumentary systembusiness.industryGastroenterologyVascular Endothelial Growth Factor DAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseVascular Endothelial Growth Factor Receptor-3digestive system diseasesLymphangiogenesisErbB ReceptorsVascular endothelial growth factor CCancer researchbiology.proteinImmunohistochemistryFemalebusinessColorectal NeoplasmsNeoplasm Transplantationmedicine.drugSignal Transduction
researchProduct

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.

2010

Background: To analyse the discriminative impact of osteopontin (OPN) and activated leukocyte cell adhesion molecule (ALCAM), combined with human epidermal growth factor 2 (HER2) and oestrogen receptor (ER) in breast cancer. Methods: Osteopontin, ALCAM, HER2 and ER mRNA expression in breast cancer tissues of 481 patients were analysed (mRNA microarray analysis, kinetic RT–PCR). Hierarchical clustering was performed in training cohort A (N=100, adjuvant treatment) and validation cohorts B (N=200, no adjuvant treatment, low-risk) and C (N=181, adjuvant treatment, high-risk). Results: Negative/low ER and HER2, high OPN and low ALCAM mRNA expression helped to identify patients at particularly h…

AdultRiskCancer ResearchosteopontinReceptor ErbB-2Eukaryotic Initiation Factor-3discriminative markersBreast NeoplasmsDisease-Free SurvivalHER2 and ER-negative breast cancerBreast cancerActivated-Leukocyte Cell Adhesion MoleculemedicineCluster AnalysisHumansOsteopontinRNA MessengerReceptorskin and connective tissue diseasesMolecular DiagnosticsALCAMALCAMAgedOligonucleotide Array Sequence AnalysisbiologyCell adhesion moleculeDecision TreesActivated-Leukocyte Cell Adhesion MoleculeCancerMiddle Agedmedicine.diseasePrognosisOncologyReceptors EstrogenImmunologybiology.proteinCancer researchFemaleBreast diseaseBritish journal of cancer
researchProduct

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St G…

2009

Background: Defining risk categories in breast cancer is of considerable clinical significance. We have developed a novel risk classification algorithm and compared its prognostic utility to the Web-based tool Adjuvant! and to the St Gallen risk classification. Patients and methods: After a median follow-up of 10 years, we retrospectively analyzed 410 consecutive node-negative breast cancer patients who had not received adjuvant systemic therapy. High risk was defined by any of the following criteria: (i) age 2 cm. All patients were also characterized using Adjuvant! and the St Gallen 2007 risk categories. We analyzed disease-free survival (DFS) and overall survival (OS). Results: The Node-…

AdultTime FactorsBreast NeoplasmsKaplan-Meier EstimateRisk AssessmentSensitivity and SpecificityDisease-Free SurvivalBreast cancerBreast cancer 3Predictive Value of TestsMedicineHumansLongitudinal StudiesProspective StudiesRisk factorAgedNeoplasm StagingRetrospective StudiesAged 80 and overNeovascularization Pathologicbusiness.industryHazard ratioCancerRetrospective cohort studyHematologyGenes erbB-2Middle Agedmedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisTreatment OutcomeOncologyAdult; Aged; Aged 80 and over; Algorithms; Breast Neoplasms/genetics; Breast Neoplasms/pathology; Breast Neoplasms/radiotherapy; Breast Neoplasms/surgery; Disease-Free Survival; Female; Follow-Up Studies; Genes erbB-2; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neovascularization Pathologic; Predictive Value of Tests; Prognosis; Prospective Studies; Receptors Progesterone/analysis; Regression Analysis; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Time Factors; Treatment OutcomeMultivariate AnalysisRegression AnalysisFemaleBreast diseasebusinessRisk assessmentReceptors ProgesteroneAlgorithmAlgorithmsFollow-Up Studies
researchProduct

Gluten affects epithelial differentiation-associated genes in small intestinal mucosa of coeliac patients

2007

Summary In coeliac disease gluten induces an immunological reaction in genetically susceptible patients, and influences on epithelial cell proliferation and differentiation in the small-bowel mucosa. Our aim was to find novel genes which operate similarly in epithelial proliferation and differentiation in an epithelial cell differentiation model and in coeliac disease patient small-bowel mucosal biopsy samples. The combination of cDNA microarray data originating from a three-dimensional T84 epithelial cell differentiation model and small-bowel mucosal biopsy samples from untreated and treated coeliac disease patients and healthy controls resulted in 30 genes whose mRNA expression was simila…

AdultTranslational StudiesGlutensDuodenummedicine.medical_treatmentCellular differentiationBiopsyImmunologyBiologyCoeliac diseaseGrowth factor receptorIntestinal mucosaGene expressionmedicineImmunology and AllergyHumansRNA MessengerIntestinal MucosaImmunity Mucosalbeta CateninEpithelial cell differentiationAgedOligonucleotide Array Sequence AnalysisReverse Transcriptase Polymerase Chain ReactionGrowth factorGene Expression ProfilingCell DifferentiationEpithelial CellsMiddle Agedmedicine.diseaseSmall intestinedigestive system diseasesWiskott-Aldrich Syndrome Protein FamilyErbB ReceptorsCeliac Diseasemedicine.anatomical_structureGene Expression RegulationImmunology
researchProduct

Epidermal growth factor receptor in human breast cancer: Correlation with cytosolic and nuclear ER receptors and with biological and histological tum…

1990

Epidermal growth factor receptor (EGFr) and cytosolic (cER) and nuclear (nER) estradiol receptors were quantified in 220 primary breast cancers. The EGFr was significantly more frequent (chi 2 = 5.9; P less than 0.025) and its concentration was significantly higher (P less than 0.001) among ER- tumors than in ER+ tumors. There was a significantly greater proportion (chi 2 = 6.4; P less than 0.05) of node involvement in EGFr+/ER+ tumors than in EFGr-/ER+. Increases in the proportion of EGFr+ in ER- tumors are parallel to Scarff-Bloom scores (chi 2 = 6.1; P less than 0.05) and there is a significant trend (Spearman rs = 0.25; P less than 0.05) towards increased EGFr concentrations with histol…

Adultmedicine.medical_specialtyBreast NeoplasmsReceptors EstradiolCorrelationCytosolEpidermal growth factorInternal medicinemedicineHumansEpidermal growth factor receptorReceptorAgedAged 80 and overCell NucleusbiologyCancerMiddle Agedmedicine.diseasePathophysiologyErbB ReceptorsCytosolCarcinoma Intraductal NoninfiltratingEndocrinologyOncologybiology.proteinHuman breastEuropean Journal of Cancer and Clinical Oncology
researchProduct

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

2018

Abstract Background Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over the 12 months of adjuvant trastuzumab in PHARE trial (NCT00381901). Methods LVEF assessment was performed every 3 months while patients received trastuzumab and after completion of treatment over the first 2 years and then every 6 months afterwards. The fluctuations of LVEF over time were described and a logistic regression model was performed investigating associated factors to LVEF perfect recovery at baseline value. Results A total of 1631 patients who received 12 months of trastuzumab from PH…

Adultmedicine.medical_specialtySide effectReceptor ErbB-2medicine.medical_treatmentBreast Neoplasms030204 cardiovascular system & hematologyVentricular Function Left03 medical and health sciences0302 clinical medicineBreast cancerAntineoplastic Agents ImmunologicalTrastuzumabInternal medicinemedicineHumansIn patientcardiovascular diseasesCardiotoxicityEjection fractionbusiness.industryGeneral MedicineMiddle AgedTrastuzumabmedicine.diseaseCardiotoxicityStandard errorChemotherapy AdjuvantEchocardiography030220 oncology & carcinogenesiscardiovascular systemCardiologySurgeryFemalebusinessAdjuvantcirculatory and respiratory physiologymedicine.drugFollow-Up StudiesBreast (Edinburgh, Scotland)
researchProduct